Dongyang Pharmaceutical (06887): Ologlizin capsules successfully included in the 2026 edition of the national medical insurance drug catalogue

Zhitongcaijing · 1d ago

Zhitong Finance App News, Dongyangyang Pharmaceutical (06887) announced that recently, the group's self-developed sodium-glucose transporter 2 inhibitor (SGLT-2 inhibitor) and the Class 1 innovative drug Ologlizin capsules (trade name: Dongzean®) were successfully included in the latest “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” published by China's National Health Security Administration. The 2026 edition of the National Medical Insurance Drug List will be officially implemented on January 1, 2027.

The product was approved for marketing by China's National Drug Administration in January 2026, and can be used as a single drug or in combination with metformin to improve blood sugar control in adult type 2 diabetes (T2DM) patients. This product is an SGLT2 inhibitor independently developed by the Group and has independent intellectual property rights. It can effectively inhibit renal SGLT2 to promote urinary sugar excretion, moderately inhibit intestinal SGLT1 to reduce glucose or galactose absorption, effectively reduce severe post-meal blood sugar fluctuations, and achieve “full, dual channel” collaborative control of fasting and post-meal blood sugar.

The product's registration approval was based on two multicenter, randomized, double-blind, controlled phase III clinical studies. Two phase III clinical studies have shown that treatment with ologlizin alone or in combination with metformin can significantly reduce glycated hemoglobin (HbA1c) for 24 weeks, comprehensively reduce fasting blood sugar and postprandial blood sugar, and bring multiple benefits such as blood pressure and weight improvement, and the curative effect stabilized until 52 weeks. It has shown outstanding effects in improving energy metabolism and is in line with the current trend of comprehensive management of diabetes “blood sugar - body weight - blood pressure”. During clinical trials, the product was generally well tolerated, and there was no significant difference in the incidence of adverse reactions from the placebo group.